OXBRYTA Drug Patent Profile

When do Oxbryta patents expire, and what generic alternatives are available?

Oxbryta is a drug marketed by Global Blood Theraps and is included in two NDAs. There are eleven patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and ninety-seven patent family members in forty-two countries.

The generic ingredient in OXBRYTA is voxelotor. One supplier is listed for this compound. Additional details are available on the voxelotor profile page.

DrugPatentWatch^® Generic Entry Outlook for Oxbryta

Oxbryta was eligible for patent challenges on November 25, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 25, 2033. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for OXBRYTA

International Patents:	297
US Patents:	11
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	48
Clinical Trials:	5
Patent Applications:	245
Drug Prices:	Drug price information for OXBRYTA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OXBRYTA
What excipients (inactive ingredients) are in OXBRYTA?	OXBRYTA excipients list
DailyMed Link:	OXBRYTA at DailyMed

See drug prices for OXBRYTA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for OXBRYTA

NDA:

213137

Dosage:

TABLET;ORAL

NDA:

216157

Dosage:

TABLET, FOR SUSPENSION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for OXBRYTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pfizer	Phase 1
Global Blood Therapeutics	Phase 2
Emory University	Phase 2

See all OXBRYTA clinical trials

Pharmacology for OXBRYTA

Drug Class	Hemoglobin S Polymerization Inhibitor
Mechanism of Action	Cytochrome P450 3A4 Inhibitors Hemoglobin S Polymerization Inhibitors

Paragraph IV (Patent) Challenges for OXBRYTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OXBRYTA	Tablets	voxelotor	300 mg and 500 mg	213137	2	2023-11-27
OXBRYTA	Tablets for Oral Suspension	voxelotor	300 mg	216157	1	2023-11-27

US Patents and Regulatory Information for OXBRYTA

OXBRYTA is protected by thirteen US patents and three FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Global Blood Theraps	OXBRYTA	voxelotor	TABLET;ORAL	213137-001	Nov 25, 2019		DISCN	Yes	No			Y	Y
Global Blood Theraps	OXBRYTA	voxelotor	TABLET;ORAL	213137-002	Oct 14, 2022		DISCN	Yes	No
Global Blood Theraps	OXBRYTA	voxelotor	TABLET;ORAL	213137-001	Nov 25, 2019		DISCN	Yes	No
Global Blood Theraps	OXBRYTA	voxelotor	TABLET;ORAL	213137-001	Nov 25, 2019		DISCN	Yes	No
Global Blood Theraps	OXBRYTA	voxelotor	TABLET, FOR SUSPENSION;ORAL	216157-001	Dec 17, 2021		DISCN	Yes	No

EU/EMA Drug Approvals for OXBRYTA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Europe MA EEIG	Oxbryta	Voxelotor	EMEA/H/C/004869Oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (SCD) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.	Authorised	no	no	yes	2022-02-14

International Patents for OXBRYTA

When does loss-of-exclusivity occur for OXBRYTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

European Patent Office

Finland

France

Guatemala

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Mexico

Morocco

Netherlands

Nicaragua

Norway

Peru

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OXBRYTA around the world.

Country	Patent Number	Title	Estimated Expiration
Luxembourg	C00276
Japan	2016512824
Portugal	3383392
Mexico	2019004120	COMPRIMIDOS QUE COMPRENDEN 2-HIDROXI-6-((2-(1-ISOPROPIL-1H-PIRAZOL -5-IL)PIRIDIN-3-IL)METOXI)BENZALDEHIDO. (TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)P YRIDIN-3-YL)METHOXY)BENZALDEHYDE.)
China	105073728

Supplementary Protection Certificates for OXBRYTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2797416	22C1042	France		PRODUCT NAME: VOXELOTOR OU UN TAUTOMERE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/21/1622 20220215
2797416	LUC00276	Luxembourg		PRODUCT NAME: VOXELOTOR OR A TAUTOMER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/21/1622 20220215
2797416	2290032-8	Sweden		PRODUCT NAME: VOXELOTOR OR A TAUTOMER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/21/1622 20220215
2797416	C202230036	Spain		PRODUCT NAME: VOXELOTOR O UN TAUTOMERO O SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/21/1622; DATE OF AUTHORISATION: 20220214; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1622; DATE OF FIRST AUTHORISATION IN EEA: 20220214
2797416	2022C/537	Belgium		PRODUCT NAME: VOXELOTOR OU UN TAUTOMERE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/21/1622 20220215

Market Dynamics and Financial Trajectory for Oxbryta

Last updated: February 20, 2026

Oxbryta (voxelotor), developed by Global Blood Therapeutics (GBT), is an FDA-approved oral therapy for sickle cell disease (SCD). Launched in 2019, it targets hemoglobin polymerization, reducing sickling of red blood cells. The following analysis covers market drivers, competitive landscape, revenue expectations, regulatory factors, and investment outlook.

Market Drivers

Unmet Need for Sickle Cell Disease Treatments:
Approximately 100,000 individuals in the U.S. have SCD, with significant morbidity and mortality. No curative treatments are widely accessible beyond hematopoietic stem cell transplantation. Oxbryta offers a disease-modifying option approved for increasing hemoglobin levels and reducing hemolysis. Its approval addresses an urgent therapeutic gap.

Growing Patient Population:
Prevalence estimates indicate an annual growth rate of 1-2% in the U.S., driven by birth rates among African American populations. Expansion into international markets, especially in regions with high SCD prevalence (Sub-Saharan Africa, India), could broaden sales.

Orphan Drug Designation:
Oxbryta holds orphan drug status, offering 7-year market exclusivity in the U.S., incentivizing sustained sales and preventing generic competition for that period.

Publication of Clinical Data:
Studies demonstrate improvements in hemoglobin and reduction of hemolytic markers, supporting label claims and patient adherence. Positive real-world evidence may expand usage beyond initial indications.

Competitive Landscape

Other Approved Therapies:

• Hydroxyurea: First-line therapy, generic, with broad usage but limited efficacy in some patients.
• Crizanlizumab: FDA-approved for preventing sickle cell vaso-occlusive crises, marketed by Novartis.
• L-glutamine: Approved in 2017, reduces oxidative damage.
• Voxelotor: First to target hemoglobin polymerization specifically.

Emerging Treatments:
Gene therapies and novel antisickling agents are in early clinical development, potentially reshaping the market in the next decade. Examples include Crispr/Cas9-based approaches and pharmacological chaperones.

Revenue Streams and Financial Trajectory

Initial Launch Performance (2019-2022):

• 2020 sales: ~$46 million
• 2021 sales: ~$77 million
• 2022 sales: ~$150 million ([1])

Projected Growth:

• GBT predicts $300–400 million in global peak sales by 2025 ([2]).
• Revenue growth depends on formulary access, physician adoption, and geographic expansion.

Pricing and Reimbursement:

• List price: approximately $125,000 annually per patient ([1]).
• Reimbursement pressure may limit net prices, especially in international markets.

Market Penetration Factors:

• Physician awareness and experience
• Insurance coverage policies
• Cost-benefit assessments by payers

Potential for New Indications:
Oxbryta's mechanism suggests possible trials for other hemolytic anemias, which could diversify revenue.

Regulatory and Commercial Challenges

Pricing Pressures:
Payers demand evidence of cost-effectiveness, which may impact pricing strategies, especially as biosimilar or generic options arise.

Access in Developing Countries:
High price point and patent protections may delay access. Partnerships with governments and global health agencies are critical for expansion.

Pipeline and Competition:
While current sales are promising, competitors' pipeline drugs and innovative gene therapies threaten market share.

Investment Outlook

Short-Term:
Strong revenue growth anticipated due to increased patient uptake and expanding indications. Near-term challenges include reimbursement negotiations and competitive pressures.

Long-Term:
Market exclusivity until 2026 in the U.S., with potential extension if patent challenges occur. The entry of biosimilars or generics post-exclusivity would impact profitability.

Strategic Recommendations:

• Focus on entering international markets with high SCD prevalence.
• Invest in physician education and patient awareness campaigns.
• Monitor emerging therapies and gene editing developments to adjust market positioning.

Key Takeaways

• Oxbryta is positioned to benefit from the unmet demand for SCD therapies, with anticipated peak sales of up to $400 million globally by 2025.
• Revenue growth will depend on formulary access, patient acceptance, and international expansion.
• Competition from generic hydroxyurea and emerging gene therapies represents both a challenge and an incentive to innovate.
• Pricing and reimbursement strategies will significantly influence net revenues.
• Long-term profitability hinges on patent protection, pipeline development, and market penetration efforts.

FAQs

1. What is the main mechanism of action for Oxbryta?
   Oxbryta binds to hemoglobin, stabilizing it in the oxygenated form, reducing hemoglobin polymerization that causes sickling of red blood cells.

2. What is the current global sales outlook?
   Analysts project $300–400 million in peak sales by 2025, with actual revenue influenced by adoption rates, pricing policies, and geographic expansion.

3. How does Oxbryta compare with other sickle cell treatments?
   It uniquely targets hemoglobin polymerization, offering a disease-modifying effect, unlike hydroxyurea, which induces fetal hemoglobin. It complements other therapies like crizanlizumab by addressing different disease pathways.

4. What are the primary hurdles for market growth?
   Pricing negotiations, payer restrictions, competition from gene therapies, and limited access in developing nations.

5. Are there plans for new indications or formulations?
   Yes. Oxbryta's pharmacology suggests potential for use in other hemolytic conditions, with ongoing clinical trials exploring such options.

---

References

[1] GBT. (2022). Oxbryta (voxelotor) sales report. Global Blood Therapeutics investor presentation.
[2] EvaluatePharma. (2023). Oncology and rare disease market forecasts.